Drugs / Recombinant Trivalent Subunit Rotavirus Vaccine
Recombinant Trivalent Subunit Rotavirus Vaccine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05621655 | Jan → Apr 2023 overdue | Rotavirus infection | MAXVAX Biotechnology Limited Liability Company | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Recombinant Trivalent Subunit Rotavirus Vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05621655 ↗ |
| Modality | Vaccine | “Recombinant Trivalent Subunit Rotavirus Vaccine” NCT05621655 ↗ |